As of May 27, 2025, Pluristem Therapeutics Inc (PSTI) reports a ROA (Return on Assets) of 53.31%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Pluristem Therapeutics Inc's ROA (Return on Assets)
Over recent years, Pluristem Therapeutics Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2021-06-30 | 53.31% |
| 2020-06-30 | -44.48% |
| 2019-06-30 | -112.78% |
| 2018-06-30 | -67.07% |
| 2017-06-30 | -74.10% |
This slight upward trend highlights how Pluristem Therapeutics Inc manages its efficiency in using assets to generate earnings over time.
Comparing Pluristem Therapeutics Inc's ROA (Return on Assets) to Peers
To better understand Pluristem Therapeutics Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Pluristem Therapeutics Inc (PSTI) | 53.31% |
| Kamada Ltd (KMDA) | 3.88% |
| Fennec Pharmaceuticals Inc (FENC) | -0.97% |
| Aileron Therapeutics Inc (ALRN) | -14.84% |
| Clal Biotechnology Industries Ltd (CBI.TA) | -20.13% |
| BioLine RX Ltd (BLRX.TA) | -23.70% |
Compared to its competitors, Pluristem Therapeutics Inc's ROA (Return on Assets) is higher than all peers, demonstrating superior efficiency in generating earnings from assets.